The estimated Net Worth of Jeno Gyuris is at least $1.37 Milhão dollars as of 6 January 2015. Jeno Gyuris owns over 4,484 units of AVEO Pharmaceuticals Inc stock worth over $1,141,965 and over the last 14 years Jeno sold AVEO stock worth over $227,782.
Jeno has made over 9 trades of the AVEO Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Jeno sold 4,484 units of AVEO stock worth $3,587 on 6 January 2015.
The largest trade Jeno's ever made was selling 5,430 units of AVEO Pharmaceuticals Inc stock on 29 January 2014 worth over $8,905. On average, Jeno trades about 1,768 units every 72 days since 2011. As of 6 January 2015 Jeno still owns at least 76,131 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Jeno Gyuris stock trades at the bottom of the page.
Jeno's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include: